|
CORSO: The multidisciplinary approach to kidney, prostate and bladder cancer Chieti, 10 May 2018 |
Direttori: Domenico Genovesi, Clara Natoli, Luigi Schips |
CREDITI ECM: 6 |
SCARICA IL PDF... |
|
|
|
|
|
|
|
|
PROGRAMMA DEL CORSO (CLICCARE SULLE ICONE PER SCARICARE LE SLIDES) |
10:00 |
Registration & Welcome coffee |
|
|
|
10:45 |
Introduction & Welcome |
|
|
|
|
Session I - KIDNEY CANCER |
Moderatori: Consiglia Carella, Katia Cannita |
|
11:00 |
Partial nephrectomy for pT2 renal tumors |
Francesco Berardinelli, Pescara |
|
|
11:20 |
Adjuvant therapy for kidney cancer: what’s going on? |
Michele De Tursi, Chieti |
|
|
11:40 |
The value of immunotherapy for kidney cancer |
Michele Milella, Roma |
|
|
12:20 |
Sequence of treatments in metastatic kidney cancer: open issues |
Giovanni Mansueto, Frosinone |
|
|
|
|
|
Session II - PROSTATE CANCER |
Moderatori: Michele Nicolai, Carlo Garufi |
|
14:00 |
Germline mutations in prostate cancer: impact on clinical practice |
Liborio Stuppia, Chieti |
|
|
14:20 |
Localized and locally advanced prostate cancer: the urologist’s point of view |
Francesco Greco, Bergamo |
|
|
14:40 |
Localized and locally advanced prostate cancer: the radiotherapist’s point of view |
Antonella Augurio, Chieti |
|
|
15:00 |
Metastatic castration sensitive prostate cancer: latest evidences & open questions |
Paolo Carlini, Roma |
|
|
15:20 |
Metastatic castration resistant prostate cancer: latest evidences & open questions |
Jamara Giampietro, Chieti |
|
|
15:40 |
Adherence and persistence to the androgen deprivation therapy |
Nicola Petragnani, Chieti |
|
|
|
|
|
Session III - BLADDER CANCER |
Moderatori: Luca Cindolo, Lucio Laudadio |
|
16:40 |
Radical cystoprostatectomy: indications to different urinary diversions |
Luigi Cormio, Foggia |
|
|
17:00 |
Bladder sparing with trimodal therapy: state of art and future perspectives |
Annamaria Vinciguerra, Chieti |
|
|
17:20 |
Immunotherapy for advanced urothelial carcinoma: a changing scenario? |
Franco Morelli, San Giovanni Rotondo (Fg) |
|
|
|
18:00 |
Take-home messages and conclusions |
|
|
|